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ABSTRACT 
Heparanase (HPSE-1) is an endo-β-D-glucuronidase that cleaves heparan sulfate chains 
of proteoglycans (HSPG), and its expression has been associated with increased growth, 
mutations, and angiogenesis of tumors.  Because metastatic melanoma cells express high levels 
of HSPG, and their tumors grow highly vascularized, we analyzed HPSE-1 expression in vivo by 
analyzing both experimental animals as well as clinical specimens with metastatic melanoma.  
Laser capture microdissection microscopy was used to isolate and extract melanoma cell 
populations from normal tissue.  There was a 29-fold upregulation of heparanase expression, 
detected by real-time PCR, by metastatic melanoma cell populations compared to normal lung 
tissue in experimental animals.  Additionally, immunohistochemistry (IHC) revealed a selective 
HPSE-1 staining in human metastatic melanoma when compared to primary melanoma tumors.  
IHC also showed a marked staining for HPSE-1 around blood vessels and vascular regions.  
Finally, we developed an orthotopic brain slice model that should aid in the study of brain cancer 
metastasis.   This model allows for the characterization of tumor invasion at both quantitative 
and qualitative levels.  Brain-metastatic melanoma cells when treated with HPSE-1 versus 
untreated cells showed a significant increase in the number of cells that invaded.  Secondly, 
melanoma cells, showed increasing HPSE-1 protein expression during a time course experiment. 
We concluded that HPSE-1 expression likely plays important roles in regulating the growth and 
progression of melanoma.  These results also further emphasize the potential importance of 
therapies designed to block HPSE-1 activity in controlling this type of cancer.           
 
 vii 
CHAPTER 1: INTRODUCTION 
Cancer is the second leading cause of death, and is a major health concern in the United 
States and in the world. Cancer metastasis, which is the spread of tumor cells from a primary site 
of origin to distant organs within the body, is a particularly important area in neoplasia as it 
accounts for 90% of cancer related mortalities (Bogenrieder et al., 2003). The brain is one of 
several highly targeted areas for metastatic cancers, and one of the highest frequencies of brain 
metastases is found in malignant melanoma (Graf et al., 1988).  Malignant melanoma has the 
unfortunate distinction of being the cancer type with the highest increase in frequency of 
occurrence, especially among young adults.  Mechanisms responsible for melanoma progression 
to highly aggressive metastatic disease are not fully understood (Bogenrieder et al., 2003) 
 Although metastatic mechanisms are not completely known, it has been demonstrated 
that metastasis is not a random event. Rather, it is the result of a complex sequence of events that 
occurs between normal host cells, tissues, and malignant cells (Bogenrieder et al., 2003; 
Nakajima et al., 1988).  Notably, all cells that metastasize must intravasate from the primary 
tumor site into the blood vessels, circulate through the blood, attach to vessel walls, exit the 
vasculature, and grow in the new surrounding tissue (Nicolson, 1982).  During the metastatic 
process, invading tumor cells must have the ability to breach tissue barriers. Degrading barriers 
such as basement membranes, extracellular matrices (ECM), and connective tissue is dependent 
on proteolytic enzymes such as heparanase (Nakajima et al., 1988).  
One of the main components of the ECM are heparan sulfate proteoglycans (HSPGs), and 
macromolecules composed of a core protein with heparan sulfate chains (HS) covalently 
attached to it. These proteoglycans are ubiquitous in the ECM and as cell surface molecules 
anchored into the plasma membrane. Recently, it has become increasingly clear that heparan 
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sulfate (HS) and heparan sulfate proteoglycans (HSPGs) play important roles in promoting tumor 
growth and metastasis. The main focus of this project was based on tumor invasiveness by the 
action of heparanase (HPSE-1), an enzyme, which plays a central role in tumor progression by 
releasing angiogenic molecules within the ECM resulting from the degradation of HSPGs. 
HPSE-1 is a recently cloned enzyme, the first and only example of purification and cloning of a 
mammalian HS degrading enzyme (Hulett et al., 1999; Kussie et al., 1999; Toyoshima et al., 
1999; Vlodavsky et al., 1999). HPSE-1 is involved in the degradation of the cell surface and 
ECM (Bernfield et al., 1999; Iozzo, 1998; Iozzo, 2001; Rapraeger, 1995; Sanderson, 2001).  
HPSE-1 is an endo-β-D-glucuronidase which cleaves heparan sulfate proteoglycans (HSPG). 
HPSE-1 has significant regulatory consequences in cancer metastasis, and its expression has 
been associated with increased growth, metastasis, and angiogenesis of tumors (Vlodavsky et al., 
2001).   
The objective of this project was to establish 1) the expression and functionality of 
HPSE-1 in malignant melanoma in vivo, and 2) to develop an organotypic culture system that 
may be useful in studying the process of brain-metastatic melanoma invasion. This model 
provides a better representation than the currently available model systems of the ECM 
molecules normally encountered by invading melanoma cells.  This brain slice model gives the 
ability to monitor tumor invasion at both quantitative and qualitative levels. For example, similar 
orthotopic brain slice models are currently being used as invasion assays for glioma cells and 
monitoring dendrite development (Nakada et al., 2004; Salama-Cohen et al., 2005)  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Historical Overview 
 Metastasis, which is the spread of cancer cells that have originated from a primary tumor 
of origin to distant loci throughout the body, is a major area of interest within the cancer research 
field. The reason for this high degree of interest resides in the fact that metastasis is the leading 
cause of cancer related mortalities. Cancer metastasis accounts for 90% of the deaths of a disease 
that is the second leading cause of death in the United States.  This makes understanding the 
metastatic process at the systemic, cellular, and molecular levels important goals of cancer 
research (Bogenrieder et al., 2003; Marchetti et al., 2003a). 
 Over 130 years ago, Stephen Paget published the ‘seed and soil’ hypothesis as an 
explanation for non-random patterns of metastatic development. This hypothesis has stood the 
test of time and is still one of two main models for the patterns of metastasis.  Paget’s hypothesis 
was centralized around the idea that metastasis was not due to chance. Instead it was the result of 
certain tumor cells (Paget called them the “seed”) that had an affinity for certain organs (Paget 
related as the “soil”). His model was that metastasis formation is dependent upon both “the seed 
and the soil” being compatible (Fidler et al., 2002).    
The other model for the spread of malignancy, proposed by James Ewing in 1932, states 
that metastasis occurs solely by a mechanical process. He stated that metastasis was the result of 
anatomical and hemodynamic factors of the vasculature. Although circulatory anatomy may 
indeed influence the dissemination of many malignant cells, it can not fully explain the patterns 
of metastatic development since there is also evidence that tumor cell properties may determine 
the outcome of malignancy (Hart et al., 1980).  
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It is important to point out that Paget’s or Ewings hypotheses should not be defined as 
mutually exclusive; rather they are both correct and overlaping to a certain extent. 
 Cancer metastasis is a process that consists of sequential and independent steps, and 
studies have shown that neoplasms go through a series of changes from the original benign 
tumor into a lethal malignant disease state. For instance, tumors can originally be benign and 
then transform into a malignancy. This has been attributed to the fact that these cells have 
generated genetic variants in order to proceed through the metastatic cascade. These genetic 
variations lead to tumor transformation and proliferation. Together with proliferation comes the 
need for development of blood vessels and extensive vascularization (named angiogenesis) in 
order to maintain tumor viability (Folkman, 1986).  Next, the malignant cells detach from the 
primary tumor and intravasate into blood vascular and lymph systems where they adhere to and 
arrest in the vasculature of distant target organs. These malignancies then extravasate through the 
blood vessel walls where they establish a tumor-host microenvironment which ultimately leads 
to cell proliferation and metastasis formation (Fidler et al., 2002).  
 Although the mechanisms for metastasis are not well understood, it is known that 
proteolytic enzymes play a role in the degradation of the ECM, which is essential for intra- and 
extravasation of tumor cells and the formation of metastasis to distant organs (Liotta, 1986). 
Therefore, a review of the role that proteolytic enzymes (specifically heparanase) and co-factors 
play in cancer metastasis development is important. 
2.2 Brain-Metastatic Melanoma 
Malignant melanoma also represents one of the best characterized solid tumors with 
respect to tumor invasion and metastatic spread (Hofmann et al., 2005). Usually the fatal step in 
the progression of many malignant cancers is often tumors metastasizing to the brain. The 
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frequency of melanoma occurrence and the morbidity of brain metastasis alone would be 
sufficient reason for alarm, but when one combines these two factors, they make the area of 
brain-metastatic melanoma a particularly important biological and clinical problem (Nicolson et 
al., 1996). 
The brain provides a unique target for malignant melanoma by being confined to the 
skull. These brain metastatic tumor cells must penetrate a formidable blood brain barrier in order 
to invade the brain tissue. Malignant melanomas metastasize to the brain with one of the highest 
frequencies of any cancers that colonize the central nervous system (CNS) (Marchetti et al., 
2003a).  Metastases to other parts of the body are generally tolerated and asymptomatic, but due 
to the confined nature of the brain, tumor formation usually results in rapid decline in health 
(Menter et al., 1994). This morbidity is usually due to cerebral edema which is a major 
complication of CNS tumors. This build up of fluid on the brain is caused by the brain’s lack of a 
lymphatic drainage system, and this creates problems for a closed environment where 
homeostasis is important for normal brain function. These characteristics of the brain 
microenvironment make treatment both difficult and necessary (Sawaya et al., 1996; Soffietti et 
al., 2002). 
2.3 The Role of the Extracellular Matrix in Cancer 
 It was originally thought that the extracellular matrix (ECM) surrounding tumor cells was 
an inert scaffold only providing for cell growth and differentiation. It is now apparent that the 
ECM plays essential roles in both normal and pathogenic cellular function and phenotype (Liu et 
al., 2002a). The current direction of thought is that the ECM is an active participant in cell 
signaling processes. This concept is based on the fact that ECM synthesis is highly regulated by 
the cell, which uses the ECM to modulate and process signals at the cell surface thereby 
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influencing cell function (Sasisekharan et al., 2000). The ECM is made of three major 
components: the first component is the structural proteins which help maintain morphology by 
providing tensile strength; the second component is proteoglycans which are protein core from 
which heparan sulfate glycosaminoglycan extensions protrude; and the last component is soluble 
signaling molecules like growth factor, cytokines, and chemokines that are bound to the ECM by 
the heparan sulfate glycosaminoglycan chains (HSGAGs) (Lin et al., 2000).  
 An important area of trying to determine the mechanism of cancer metastasis and 
development is the proteoglycan component of the ECM. There is much interest in proteoglycans 
because they are present both in the ECM and at the cell surface, thus they are directly involved 
in the cell-tissue interface. Proteoglycans are involved in both how the cell processes signals that 
arise from the ECM, and also, how a signaling molecule that is released from the cell diffuses to 
and is processed at a distant site (Liu et al., 2002a). 
2.4 The Function and Structure of Proteoglycans 
 Proteoglycans are a superfamily of molecules that are distinguished by the covalent 
attachment of one or more glycosaminoglycan chains (GAG) to a polypeptide core. Differences 
in GAG composition are used to discern the four classes of GAGs that attach to core proteins: 
chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS)/heparin, and keratin sulfate 
(KS). The proteoglycans of interest are usually heparan sulfate proteoglycans (HSPGs) this is 
because cell suface proteoglycans primarily have HS attached to them. Virtually all cells express 
HSPGs at their cell surface, and a large number of genetic mutants that disrupt HS synthesis and 
modification demonstrate that HS has a critical role in controlling how cells interact with 
extracellular ligands (Kramer et al., 2003). 
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 Two families of polypeptides appear to carry the majority of the cell surface heparan 
sulfate on mammalian cells: glypicans, which are attached to the plasma membrane via 
glycosylphosphatidylinositol (GPI) anchors, and syndecans, which are transmembrane proteins. 
Four syndecans and five glypicans, all encoded by separate genes, have been described to date 
(Bernfield et al., 1992). HSPG expression is developmentally regulated and altered in various 
pathological processes, including cancer. The expression patterns are believed to mirror those of 
ligands that require HSPGs to elicit their cellular responses. For instance, syndecan-1 cell surface 
expression is usually down-regulated in metastatic phenotypes. At the same time, syndecans are 
shed from the cell surface as soluble molecules that regulate protease and growth factor activity, 
and this soluble syndecan expression in tumors has been correlated with increased cancer 
progression and invasion (Sanderson, 2001). 
2.5 The Structure and Variability of Heparan Sulfate Glycosaminoglycans (HSGAGs) 
 HSGAGs are ubiquitously expressed on the surface of every eukaryotic cell and have 
shown importance in the regulation of normal and pathological physiology (Sasisekharan et al., 
2002).  HSGAGs are synthesized in the Golgi apparatus beginning with four monosaccharides 
linking to the proteoglycan core protein, usually either a syndecan or a glypican. This chain is 
then turned into a polysaccharide by the sequential addition a glucosamine linked to either 
iduronic or glucuronic, and there are many possible disaccharide unit combinations for HSGAGs 
(Gallagher, 2001). These different possibilities are based on the fact that O-sulfation can occur at 
the 2-O position of uronic acid and at the 6-O and 3-O positions of the glucosamine. This creates 
eight different combinations because each site can be either sulfate or unsubstituted. There is 
also the opportunity for sixteen additional different combinations of disaccharides by the fact 
that there are two possibilities for the uronic acid component which can be either iduronic acid or 
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glucuronic acid. Lastly, the N-position of the glucosamine has three possible states in that it can 
be either sulfated, acetylated, or unsubstituted, which results in 48 different possibilities for 
disaccharide building blocks. This gives HSGAGs over 30 times as many possible variations as 
that of polypeptides and 10,000 times that of DNA, having the potential for a staggering degree 
of variation (Esko et al., 2001).  
 The result of HSGAGs having such a vast structural diversity is that they have the ability 
to bind and interact with a various array of proteins which includes growth factors, chemokines, 
morphogens, and enzymes. Growth factors, such as insulin like growth factor, basic fibroblast 
growth factor (bFGF), platelet-derived growth factor (PDGF), and vascular endothelial growth 
factor (VEGF), have shown to have important roles in the process of tumor development (Iozzo, 
2001; Marchetti et al., 2003b; Nurcombe et al., 2000; Sasaki et al., 2004). The specificity of 
these interactions is dependent on HSGAG sequence, spacing of binding sites, and the three-
dimensional structure of the HSGAG chain. These various HSGAG functions are important for 
both signaling molecules and enzymes to function in an appropriate manner.  
2.6 HSGAGs in Cancer Development and Metastasis 
 HSGAGs have been shown to be involved in the transformation of a normal target cell to 
a cancer cell. It has been demonstrated that HSGAGs present on tumor cells contain bioactive 
sequences that effect several aspects of tumor-cell phenotype in relation to cell growth and 
metastasis. Tumor cell surface HSGAGs can promote growth factor signaling and tumor cell 
proliferation (Sasisekharan et al., 2002). The fibroblast growth factor receptor (FGF) family, 
which has diverse roles in regulating cell proliferation, migration, and differentiation when 
inappropriately expressed, can contribute to the pathogenesis of cancer. There are numerous 
levels of evidence implicating the differential ability of HSGAGs in regulating FGF signaling via 
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their cell surface tyrosine kinase receptors (FGFR). For example, it has been observed that the 
specificity of a given FGF to a FGFR is mediated by what appears to be distinct tissue-specific 
HSGAG sequences, and tumor cells have been reported to control the affinity that HSPGs and 
growth factors like basic fibroblast growth factor (bFGF) have for each other by altering the 
density and sulfation patterns of their HSPGs (Sasisekharan et al., 1994). The expression of and 
the structural integrity of HSGAGs on the cell surface have shown to change with the metastatic 
transformation of certain cell types (Kure et al., 1987). For example, it has been shown that B16 
melanoma cells with high metastatic propensities have a lower concentration of cell surface 
HSGAGs than sublines with less metastatic potential. It has also been shown that highly 
metastatic B16 sublines degrade HSGAGs faster than sublines of lower metastatic spread 
(Nakajima et al., 1983) 
 HSGAGs are not randomly involved in cancer metastasis, rather they play intricate roles 
in this multi-step process. In order for a tumor to develop beyond a diameter size of 1-2 mm, an 
increase in vascularity is necessary, and HSGAGs are directly involved with the angiogenic 
process (Iozzo, 2001). In fact, bFGF has a dual role in its interaction with HSGAGs in that it is 
involved with tumor growth, and it is also involved with the development of new blood vessels. 
HSGAGs which are present on endothelial cells can indirectly effect tumor growth; they can 
either enhance or inhibit neovascularization by regulating signal transduction of bFGF or 
vascular endothelial growth factor (VEGF). In addition, HSGAGs have dual roles in tumor 
metastasis as well. Since HSGAGs are at the interface between tumor cells and normal host cells, 
it allows for them to mediate tumor and host cell interactions (Raman et al., 2003). HSGAGs 
regulate tumor metastasis to sites such as the brain by arbitrating interactions between cancer 
cells and platelets and endothelial cells and host organ cells (Varki et al., 2002). HSGAGs are 
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also involved in attempts to deter metastasis by acting like barriers in the ECM. This HSGAG 
barrier, however, is overcome by invading tumor cells that secrete degradative enzymes. Studies 
have shown a direct correlation between the production of heparanase, an enzyme that degrades 
the polysaccharide component of the ECM, and the invasiveness of tumor cells (Vlodavsky et 
al., 2001). 
2.7 The Function of Heparanase in Tumor Progression and Metastasis 
 Heparanase (HPSE-1) is an enzyme that was first identified in the B16 murine metastatic 
melanoma cell sublines (Hook et al., 1975). It was shown in these B16 sublines that HPSE-1 
correlated with lung metastasis potential (Nakajima et al., 1983). Since that time, HPSE-1 has 
been linked to a wide number of cancers including bladder, colon, gastric, breast, pancreatic, and 
brain (Friedmann et al., 2000; Gohji et al., 2001; Koliopanos et al., 2001; Marchetti et al., 2001; 
Maxhimer et al., 2002; Tang et al., 2002). This suggests that HPSE-1 plays a role in the sustained 
development and pathology of malignant diseases and would make a good potential target for 
cancer therapy (McKenzie et al., 2003).  
Heparanase is an endo-β-D-glucuronidase that affects various biological processes 
through degradation of the ECM and release of HS-bound growth factors, cytokines, and 
enzymes. Heparanase participates in ECM desolation by invading cells, and HPSE-1 enzyme 
activity has been detected in several types of normal hematopoietic cells, including neutrophils, 
megakaryocytes, and activated lymphocytes and may mediate their extravasation during 
inflammatory and immune responses (Matzner et al., 1992; Nakajima et al., 1988; Schubert et 
al., 2004). Additionally, heparanase has been identified as a participant of embryogenesis (Revel 
et al., 2005), but is mainly known for its role in cancer invasion and metastasis. HPSE-1 does 
more than simply degrade and remodel extracellular matrix. HPSE-1, rather than fully digesting 
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HSGAGs, cleaves HSGAGs at only a few sites, producing fragments that are 10–20 sugar 
residues long. There is also evidence that the fragments of heparan sulfate generated by 
heparanase are more biologically active than the native HSGAGs from which they are derived 
(Sanderson et al., 2004). The human HPSE-1 gene is located on chromosome 4 and encodes a 
543-amino-acid protein that has recently been purified and cloned (Hulett et al., 1999; Kussie et 
al., 1999; Toyoshima et al., 1999; Vlodavsky et al., 1999). This protein was originally 
synthesized as a 65 kDa glycosylated pro-enzyme that is activated by proteolytic cleavage to 
remove a linker region and form an active heterodimer of 8 and 50 kDa polypeptides (Fairbanks 
et al., 1999). The hydrolase activity of HPSE-1 works by cleaving the linkage between the 
glucuronic acid and N-acetylglucosamine of the HSGAGs (Nakajima et al., 1983). The HPSE-1 
enzyme activity is closely regulated by pH, achieving maximal activity under acidic conditions at 
an optimum range between a pH of 5.5-8.8. This characteristic of HPSE-1 activity correlates 
well with the notion that the microenvironment in tumors is generally more acidic than in normal 
tissues. This acidity of the tumor microenvironment is found within hypoxic areas of growing 
tumors (Tannock et al., 1989). Upon activation in this acidic environment, HPSE-1 facilitates the 
release of several protein modulators that effect cell functions such as migration, adhesion, 
inflammation, and angiogenesis. HPSE-1 activation then facilitates processes which are all steps 
in the development of metastatic invasion (Hulett et al., 1999; Kussie et al., 1999; Nakajima et 
al., 1988; Parish et al., 1987; Toyoshima et al., 1999; Vlodavsky et al., 1999; Vlodavsky et al., 
2001; Zetser et al., 2003). 
2.8 Neurotrophins in Brain Metastasis and Heparanase Production 
Metastasis is not a random event, and there are reasons that metastasis frequently occurs 
in certain organs. The reasons for these metastatic patterns may lie within the stromal cells and 
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the paracrine growth and differentiation factors that they secrete (Marchetti et al., 2004). The 
first one of these factors to be purified and characterized was nerve growth factor (NGF). NGF is 
important for the survival of and differentiation of neurons in both the sympathetic and central 
nervous system (Marchetti et al., 1993). NGF is the prototype of a family of neurotrophins (NT) 
which are a group of neurotrophic factors that are distinct from cytokines and FGFs. Although 
NGF is the best characterized NT, it is also known that other family members like brain derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are also 
involved as neurotrophic substances as well. The biological effects of NTs are mediated through 
two unrelated classes of cell surface membrane receptors.  All NTs can bind to p75 neurotrophin 
receptor (p75NTR) which is a low-affinity receptor. There is, however, a family of high-affinity 
Trk receptors that are bound selectively by certain NTs. For instance, NGF binds TrkA, BDNF 
and NT4/5 bind TrkB, and NT-3 binds TrkC (Chao et al., 2002).   When NT receptors (NTR) are 
overexpressed in melanoma cells, they have shown to be more aggressive and have a stronger 
survivability than cells that express low NTR levels (Marchetti et al., 2004). Binding of NGF 
along with p75NTR being overexpressed has been characterized as giving cells both a survival 
advantage and creating aggressive malignant melanoma cells. There are previous studies that 
have shown that cells incubated with select NTs showed an increased ability to invade into a 
membrane like matrix, but what was of greater interest is the fact that these NTs caused an 
increase in HPSE-1 activity. The result is an NT-driven degradation of the ECM by HPSE-1 
(Walch et al., 1999).    
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CHAPTER 3: SELECTIVE HEPARANASE LOCALIZATION IN MALIGNANT 
MELANOMA CANCERS 
 
3.1 Introduction 
 
Malignant melanoma has the unfortunate distinction of being the cancer type with the 
highest increase in frequency of occurrence, especially among young adults.  Mechanisms 
responsible for melanoma’s progression to a highly aggressive metastatic disease are not fully 
understood.  However, it is known that proteolytic enzymes play important roles due to their 
involvement in extracellular matrix (ECM) disassembly which allows melanoma cells to invade 
distant organs (Bogenrieder et al., 2003).  Heparanase (HPSE-1) plays a critical role in tumor 
progression by degrading the heparan sulfate (HS) chains of HS proteoglycans (HSPG) and by 
releasing angiogenic molecules stored within the ECM(Vlodavsky et al., 2001).  HSPG are 
present on the cell surface and in the ECM of tissues and their degradation has significant 
regulatory consequences in cancer metastasis (Nardella et al., 2004).   HPSE-1 is an enzyme that 
was cloned in 1999 (Hulett et al., 1999; Kussie et al., 1999; Toyoshima et al., 1999; Vlodavsky 
et al., 1999)as the first and thus far the only example of purification and cloning of a mammalian 
HS degradative enzyme.  HSPE-1 acts as an endo-β-D-glucuronidase cleaving HS glycosidic 
bonds at specific intrachain sites resulting in the formation of fragments of appreciable size (10-
20 sugar units) (Nakajima et al., 1984; Nakajima et al., 1988; Vlodavsky et al., 2001). Its 
hydrolase activity facilitates the release of several protein modulators that affect cell functions 
such as migration, adhesion, inflammation, embryogenesis, angiogenesis, and metastatic 
invasion (Hulett et al., 1999; Kussie et al., 1999; Marchetti et al., 1993; Marchetti et al., 1996; 
Nakajima et al., 1988; Toyoshima et al., 1999; Vlodavsky et al., 1999; Vlodavsky et al., 2001). 
Furthermore, elevated HPSE-1 mRNA levels correlate with reduced survival rates in post-
*Chapter 3 reprinted by permission of Professor D.A. Spandidos, the editor of International 
Journal of Oncology. 
 13 
operative cancer patients (Vlodavsky et al., 1999; Vlodavsky et al., 2001). These observation led 
us to hypothesize that HPSE-1 would be substantially elevated in melanoma tissues particularly 
when compared to normal tissues from the same specimen.  In the present report, we provide 
first evidence that 1) HPSE-1 mRNA is significantly upregulated in lung metastatic melanoma 
versus adjacent lung tissue; 2) HPSE-1 protein expression is significantly augmented in 
metastatic melanoma clinical specimens while mostly negative in primary tumors; and 3) HPSE-
1 accumulates around blood vessels and vascular regions in brain-metastatic melanoma 
specimens. 
3.2 Materials and Methods 
3.2.1 Tissue Culture and Experimental Metastasis Assays 
Early-passage murine invasive melanoma cells (B16F1, B16F10 and B16B15b) were 
maintained as monolayer cultures in a 1:1 (v/v) mixture of Dulbecco’s modified Eagle’s/ Ham’s 
F-12 medium (DMEM/F-12) supplemented with 5% fetal bovine serum (FBS) (v/v).   Cells were 
maintained at 37°C in a humidified 5% CO2/95% air (v/v) atmosphere and were passaged using 
2 mM Ethylene Diamine Tetra Acetic Acid (EDTA) in Phosphate buffered saline (PBS) before 
reaching confluence, as previously reported (Marchetti et al., 1993; Marchetti et al., 1996). 
Eight-week old female C57BL/6 mice were obtained from Harlan Sprague Dawley and 
quarantined for 1 week.  The mice were randomly divided into three groups with four mice in 
each group receiving an injection of B16F1, B16F10, or B16B15b cells respectively.  Injection 
in the lateral tail vein (I.V.) was carried out using 2 x 106 cells suspended in serum-free medium 
(200 µl).    Mice were sacrificed after 17 days when they were moribund due to dyspnea.  
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 3.2.2 Surgical Specimens 
Specimens were obtained from the Cooperative Human Tissue Network, Tissue 
Procurement Facility, University of Alabama at Birmingham, AL, and from the Surgery 
Department at the University Hospital of Udine,  Italy.   These specimens were obtained frozen 
or were cut  into 2x2x1 cm fragments, fixed in the 10% buffered formalin and paraffin 
embedded.   Sections (5 µm thick) were cut into sialinized slides.  Following treatment, slides 
were immunostained and examined in the Department of Pathobiological Sciences at the 
Louisiana State University School of Veterinary Medicine to identify tumor samples that 
contained metastatic melanoma as well as adjacent normal lung tissue.  This resulted in the 
selection of 10 cases of brain-metastatic melanoma with adjacent brain tissue, 25 cases with 
metastatic melanoma to sites other than brain, and 10 cases of primary melanomas. 
3.2.3 Tissue Preservation 
Freshly dissected lungs were collected from mice, washed in cold diethylpyrocarbonate 
(DEPC)-treated PBS, and then incubated at 4°C on a rocking platform for 24 hrs in 30% sucrose 
(Parlato et al., 2002).  The tissue was again rinsed with PBS and flash frozen in isopentone over 
dry ice.   Frozen sections were embedded in optimal cutting temperature medium (OCT) and 
mounted on a cryomold.    Sections were subsequently cut (10 µm thick) at -25°C, fixed in 
decreasing concentrations of ethanol (100 % EtOH, 70 % EtOH, and 50 % EtOH) for 20 sec 
each, stained for 20 sec with cresyl violet acetate, and then again dipped in 50 % EtOH, 70 % 
EtOH and in 100 % EtOH (two times).  Slides were air-dried and stored at -80°C until used. 
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3.2.4 Laser Cpture Mcrodissection Mcroscopy and RNA Extraction 
Laser capture microdissection microscopy (LCMM) (Emmert-Buck et al., 1996; Fend et 
al., 1999; Sugiyama et al., 2002) was performed using the P.A.L.M. Laser-MicroBeam System 
(P.A.L.M., Wolfratshausen, Germany) following protocols provided by the manufacturer.   The 
P.A.L.M. system was used to dissect normal tissue from tumorigenic tissue for the differential 
analysis of heparanase levels.    Previously prepared slides were removed from -80°C just prior 
to use to avoid potential RNA degeneration. The P.A.L.M. system catapulted tissue (104 to 1.5 x 
104 cells) into the lid of a reaction tube covered with extraction buffer (0.5 ml; Arcturus Inc., 
Mountain View, CA).    The cap was inserted onto the reaction tube and the assembly was kept 
on ice.   Following an incubation step at 42°C for 30 min, total RNA was extracted following the 
suggested protocol using the PicoPure RNA Isolation Kit (Arcturus Inc.).   RNA was eluted 
using the kit elution buffer (18 µl).    Presence of RNA was confirmed by PCR with the 
housekeeping gene GAPDH for murine samples and β-actin for human samples (Kreuzer et al., 
1999; Overbergh et al., 1999). 
3.2.5 cDNA Synthesis and PCR Amplification 
cDNA synthesis was performed with a reverse transcription (RT)-mixture (25 µl; 
Promega, Madison, WI).   First, RNA (13 µl) was incubated with 0.3 µg of oligo dTs 
(Invitrogen, Grand Island, NY) at 70°C for 5 min.   Then, 5 µl of 5x RT buffer, 0.5 mM dNTPs, 
25 units of RNAsin, and 200 units of M-MLV (Promega) were added, and the final RT-mixture 
was incubated at 42°C for 50 min with a heating step to 94°C for 2 min. PCR reactions were 
performed with a PCR-mixture (25 µl) consisting of cDNA (2 µl), 2.5 µl of 10x PCR buffer, 0.2 
mM dNTPs, 0.5 µM primers, and 1 unit of Taq Polymerase (Promega).   PCR was first 
performed with the housekeeping genes GAPDH (for murine samples) and β-actin (for human 
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samples) to check for viable RNA.   Samples testing positive for GAPDH or β-actin were tested 
for the HPSE-1 presence.  Amplification was performed using the GeneAmp PCR-system 9700 
(Applied Biosystems, Foster City, CA).   Human samples had an initial denaturation step at 94°C 
for 5 min which was followed by 40 cycles of denaturation at 94°C for 30 sec and an 
annealing/extension step at 67°C for 60 sec for human β-actin or 60°C for 60 sec for human 
heparanase and murine GAPDH.  The conditions for murine heparanase were 94°C for 5 min 
followed by 35 cycles at 94°C for 30 sec, 60°C for 45 sec, and 72°C for 45 sec with a final 
extension at 72°C for 10 min.  Primer sequences and expected amplicon sizes are listed in Table 
1. Agarose (1%) gel electrophoresis was subsequently performed. 
3.2.6 Real-Time PCR 
The fluorogenic probe used for real-time PCR analyses of murine heparanase contained 
the reporter dye FAM covalently attached at the 5’-end and a quencher dye TAMRA at the 3’-
end (Applied Biosystems).  The endogenous control used for murine samples in this study was 
18S ribosomal RNA (Applied Biosystems), the reporter dye for 18S was VIC and the quencher 
dye was TAMRA.   All fluorogenic probes were HPLC-purified.  Analysis was performed using 
the ABI PRISM 7700 sequence detection system (Applied Biosystems).  Amplification was 
carried out in a reaction volume (30 µl) that consisted of cDNA solution (2.5 µl) from the RT 
reaction, 2x TaqMan Mastermix (Applied Biosystems), 900 nM heparanase primer or 50 nM of 
18S primer, and 200 nM of each probe in ddH2O.   Amplification was performed in triplicate in 
MicroAmp optical tubes using the standard amplification protocol as recommended by the 
manufacturer.  
 
 
 17 
3.2.7 Quantification of HPSE-1 mRNA Expression  
Using the internal fluorogenic oligonucleotide probes, each well was monitored for 
fluorescent dyes, and signals were regarded as significant if the fluorescent intensity statistically 
exceeded (10-fold) the standard deviation of baseline fluorescence as Threshold cycle (CT).  CT 
was defined as the cycle at which a significant increase in emission intensity was first detected.  
Relative mRNA quantitation was performed using 18S as the housekeeping gene and the 
comparative ∆∆CT-method as previously described (Brink et al., 2000).  
3.2.8 Immunohistochemistry for Murine Samples 
Immunohistochemical staining was performed using a Vectastain ABC kit (Vector 
Laboratories, Inc., Burlingame, CA) according to the instructions provided by the manufacturer.  
Formalin-fixed, paraffin-embedded tissue sections were mounted on silanized slides (Fisher 
Scientific, Springfield, NJ) and deparaffinized.  Endogenous peroxidase was blocked by 
incubating the sections in H2O2  (3.0%).  After the blocking of nonspecific reactivity with rabbit 
serum for 30 min at room temperature (25°C),  sections  were  incubated at  4°C  for 60 min 
using HPSE-1 rabbit polyclonal antibody raised against human HPSE-1 and crossreacting with 
the murine enzyme (Pharmacia-Upjohn Inc., Kalamazoo, Michigan).  Following rinsing, slides 
were incubated with biotinylated anti-rabbit IgG and then with Vectastain ABC reagent.   
Peroxidase activity was determined using the NovaRED substrate kit (Vector Laboratories Inc.), 
and the slides were counterstained with Mayer’s hematoxylin.  As a negative control, sections 
were subjected to normal serum blocking with omission of the primary antibody. 
3.2.9 Immunohistochemistry for Human Samples 
Sections were prepared from human melanoma tissue samples which had been formalin-
fixed and paraffin-embedded.  The tissues were sectioned at 5 µm, mounted on silanized slides, 
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heated, deparaffinized, and rehydrated.  Endogenous peroxidase was blocked with a H2O2 
solution (3.0%).  Slides were pretreated with proteinase K and then blocked with horse serum.   
Sections were incubated at room temperature (25°C) for 30 min using a mouse monoclonal 
antibody raised against human HPSE-1 (2 mg/ml, diluted 1:200 and 1:500) (Tsukuba Research 
Institute, Novartis Pharma K.K., Takarazuka, Japan).  Additionally, a mouse monoclonal 
antibody directed against human endothelial marker CD34 was also used (Cell Marque, Hot 
Springs, AR).   Following rinsing, slides were incubated with biotinylated goat anti-mouse IgG 
and then with Vectastain ABC reagent (Vector Laboratories).  Peroxidase activity was 
determined using the NovaRED substrate kit (Vector Laboratories), and slides were 
counterstained with Mayer’s hematoxylin.  Control sections were treated identically but an 
isotyped matched mouse monoclonal antibody was used as the primary antibody.   
3.2.10 Statistical Analysis 
Staining of each section was assigned scores ranging from 0 to 4+ as follows: negative 
(0), weakly positive (1+), moderately positive (2+), positive (3+), and highly positive staining 
(4+).   For IHC determinations, positive cases were those that stained with an intensity score of ≥ 
1, baseline mark for staining positivity. 
All results comparing tumorigenic tissue versus normal tissue were analyzed using the paired 
Student’s t-test.  They were considered significant if p < 0.05.  
3.3 Results 
3.3.1 Melanoma Development in Mice 
To examine for HPSE-1 presence, mice were inoculated with B16F1, B16F10, or B16B15b 
melanoma cells and sacrificed 17 days later when they exhibited severe signs of dyspnea.  
Necropsy was performed with primary emphasis on lung tissue, and necropsy showed severe 
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infiltration of this tissue with black fragile nodules.   Histological analyses confirmed the 
pulmonary nodules to be melanoma metastasis.   A representative experiment showing of lung-
metastatic melanoma in a mouse injected with B16F10 cells is shown (Figure 3.1). 
3.3.2 Localization of HPSE-1 in Metastatic Melanoma Lesions 
 In  order to obtain the precise RNA content of melanoma tissue, we employed laser 
capture microdissection microscopy (LCMM) to avoid contamination between cancerous and 
normal tissue samples.    LCMM is beneficial because it allows for specific isolation of very 
small tissue samples (Emmert-Buck et al., 1996; Fend et al., 1999; Parlato et al., 2002; Sugiyama 
et al., 2002).  Furthermore, LCMM makes real-time PCR (RT-PCR) and PCR analysis of very 
small tissue samples more feasible and reproducible.   Melanotic and normal pulmonary cells 
could be efficiently isolated into different samples. Since the cancer metastasized to the lung, we 
used similar populations of normal lung tissues as controls for HPSE-1 analysis.  The process of 
laser capture microdissection of melanoma tissue is shown in Figure 3.2. 
In order to confirm that RNA extractions worked, PCR was performed on all samples as 
shown (Table 3.1).  In murine samples, PCR was performed using GAPDH as the housekeeping 
gene.  The GAPDH gene showed good RNA extractions in ten out of twelve samples, and 
samples that tested negative were from the two mice that died before they could be euthanized.  
Once the samples tested positive for the housekeeping gene, analysis for murine heparanase was 
performed.  The PCR for murine heparanase demonstrated the expected 205 bp band in the 
tumor samples;  however, all samples from adjacent normal tissue tested negative for HPSE-1 
cDNA presence (Figure 3.3).   
3.3.3 HPSE-1 mRNA is Upregulated in Murine Melanoma Tissues               
Because HPSE-1 has been shown to be involved in cancer invasion, angiogenesis,  
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Figure 3.1 A Representative Experiment of Lung-Metastatic Melanoma.  
Murine malignant melanoma cells were injected intravenously (tail vain injection) in 6-week old 
female mice (C57BL/6).  At the end of experimental period, mice were euthanized, and the lungs 
with metastatic melanoma were extracted and preserved for subsequent analysis. 
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Figure 3.2  Detection and Extraction of Melanoma Cells in Lung Tissues by LCMM.  
Sections before (A) and after (B) LCMM, showing the remaining cells on the slide.  NLT, 
normal lung tissue. Melanoma cells are indicated. 
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Table 3.1  Sequences of PCR Primers and Sequence Specific Probes for Different  
Targets. 
 
Target 
Sequence Primer Sequence  (5’-3’) 
Amplicon 
Length 
(bp) 
GAPDHa 
forward 
probec 
reverse 
TTCACCACCATGGAGAAGGC 
TGCATCCTGCACCACCAACTGCTTAG 
GGCATGGACTGTGGTCATGA 
236 
18Sa probed Supplied by Perkin Elhmer (4308310) 187 
HPSE-1a 
forward 
probec 
reverse 
GACAAGGAACCGACTTCCGAAGAA 
Performed by Perkin Elhmer 
CTGTAGAGCATGTCCACTGAGCTT 
205 
GAPDHb probee Supplied by Perkin Elhmer (402869) 226 
β-actinb forward reverse 
AGCCTCGCCTTTGCCGA 
CTGGTGCCTGGGGCG 180 
HPSE-1b 
forward 
probec 
reverse 
TCGTGGACCTGGACTTCTTCA 
CCACGGACCCGCGGTTCCT 
ACAAGCCTCTGGCCAAGGTA 
150 
aSequence for murine sample 
bSequence for human sample 
 
cFAM-labeled DNA probe 
dVIC-labeled DNA probe 
eJOE-labeled DNA probe 
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Figure 3.3  Agarose Gel Electrophoresis Showing PCR for Expression of Murine 
heparanase in Metastatic Melanoma and Adjacent Lung Tissues Obtained by 
LCMM.   
(A) Lanes 1 to 8: melanoma tissue samples; Lane 9: negative control (H2O); Lane 10: positive 
contol (B16F10).  (B) Lanes 1 to 9: normal lung tissue samples; Lane 10: negative control 
(H2O); Lane 11: positive control (B16F10).  
 
 
 
and metastasis, we determined comparative and quantitative HPSE-1 mRNA levels in tumor 
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versus normal tissues.   We performed real-time PCR to determine whether heparanase is 
upregulated in metastatic tissue versus normal tissues.    The first choice as a murine 
housekeeping gene for sample normalization was murine GAPDH.  With GAPDH as the 
housekeeping gene there was a marked difference in CT values between normal tissue and tumor 
tissue throughout all samples. This difference was up to 16 CT values difference between 
samples, which corresponds to a 216 or 65,536-fold difference.  For this reason, GAPDH could 
not be used for the housekeeping gene.  Analysis of ribosomal 18S expression as a different 
housekeeping gene showed a similar result, but the trend was not nearly as profound.  Data of 
quantitative expression analysis for HPSE- 1 was normalized to the housekeeping gene 18S 
(Table 3.2).   The melanoma samples after normalization had an average ∆CT value of 10, and 
the average ∆CT value for normal lung was 14.86 (Table 3.2). The average calculated ∆∆CT 
value (normal minus melanoma) was 4.86, which corresponds to a 29-fold increase of 
heparanase mRNA expression in melanoma tissue (Figure 3.4).  Results for ∆∆CT were shown to 
be significant to p < 0.05.  CT values for individual sample ∆CT’s are indicated in Table 3.2.  
3.3.4 Elevated HPSE-1 Expression in Metastatic Melanoma Lesions 
Immunohistochemistry was performed for the presence of heparanase with anti-HPSE-1-
PAb on paraffin-embedded, lung-metastatic samples from mice.    We observed an intense 
immunostaining for heparanase detected on the cell-surface and ECM for each of melanoma 
tumors samples. A representative experiment HPSE-1 immunostaining is shown in Figure 3.5. 
Immunostaining for HPSE-1 also tested positive in all human samples of metastatic melanoma.  
Conversely, primary melanoma tumors were mostly negative for HPSE-1.  In metastatic 
melanoma to brain, 8 cases had very intense staining for HPSE-1 (Figure 3.6).  Of note, HPSE-1 
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Table 3.2  Comparison of HPSE-1 mRNA in Adjacent Normal and Metastatic Melanoma 
Tissues Melanoma by Quantitative Real-Time PCR.  
 
a Samples were normalized against the housekeeping gene 18S.  
 ∆ CT 
melanoma tissue 
∆ CT 
normal tissue 
∆∆ CT  
Mouse 1 6.8a 14.0 7.2  
Mouse 2 N.D.b 15.0 N.D. Average  
Mouse 3 9.1 13.9 4.8 ∆∆ CT = 4.91 
Mouse 4 9.9 15.7 5.8  
Mouse 5 15.5 16.0 0.5  
Mouse 6 N.D. 17.3 N.D. Average fold  
Mouse 7 9.5 10.1 0.6 difference 
Mouse 8 10.0 14.0 4.0 F = 24.9 = 29.1 
Mouse 9 9.8 N.D. N.D.  
Mouse 10 9.6 17.8 8.2  
Average 
Std.dev. 
10.0c 
2.44 
14.9c 
2.29 
  
b N.D. = not detectable. 
c Statistically significant at p < 0.05. 
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Figure 3.4  HPSE-1 Quantification in Normal Versus Melanoma Tissues.   Quantitation 
levels were detected by TaqmanTM RT-PCR followed by ∆∆CT analysis. Mice were injected with 
murine melanoma cells (B16F1, B16F10, or B16B15b).  Once the mice showed signs of 
dyspnea, they were sacrificed, and total RNA was isolated from normal (9 samples) and 
tumorigenic (8 samples) lung tissue. Optimized reverse transcription of RNA and amplification 
of specific cDNA were performed using the ABI Prism 7700 Sequence detection system 
(Applied Biosystems;  see also “Materials and Methods”). Significant PCR fluorescent signals 
(CT) for heparanase were normalized to an endogenous reference (18S). RT-PCR was performed 
in triplicates.  Data were considered significant if p < 0.05. 
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Figure 3.5  HPSE-1 Immunostaining in Murine Metastatic Melanoma.   
Mice (C57 BL/6) were injected with melanoma cells and subsequently lung-metastatic 
melanomas were extracted and formalin fixed for immunohistochemistry.  Intense peroxidase 
staining of HPSE-1 was observed using anti-HPSE-1 PAb (see also ”Materials and Methods”).    
(A) Hematoxylin and eosin staining. (B) Anti-HPSE-1 PAb staining. (C) Nuclei stained by 
hematoxylin as a negative control.   Digital images were produced on an Axioplan microscope 
with Advanced Spot imaging program (Diagnostic Instruments Inc., Sterling Heights, MI) with 
20x objective using identical conditions for all photographs. 
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Figure 3.6  HPSE-1 Expression in Human Melanoma Tissues.   
HPSE-1 immunohistochemical analyses of clinical specimens were performed as described in 
Materials and Methods using the anti-human HPSE-1 monoclonal antibody. Primary tumor (A-
C) staining was negative for HPSE-1 (B) while immunostaining of lymph node tumor tissue (D-
F) showed moderate positivity for heparanase (E).   However, brain-metastatic melanoma tissue 
(G-I) showed intense staining for heparanase (H).  Digital images were produced on an Axioplan 
microscope with Advanced Spot imaging program (Diagnostic Instruments Inc., Sterling 
Heights, MI) with 20x objective using identical conditions for all photographs.  Hematoxylin and 
eosin slide (A, D, G), Anti-HPSE-1-MAb staining (B, E, H), and nuclei stained by hematoxylin 
as a negative control (C, F, I). 
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was found to aggregate around blood vessels in four out of eight brain metastatic melanoma 
samples (Figure 3.7), which was not unexpected due to the role that heparanase plays in 
angiogenesis. Vascularity was confirmed by staining with CD34 antibody (Kelly et al., 2003). 
3.4 Discussion  
In this study, we examined the relationship between the in vivo expression and 
localization of the ECM degradative enzyme heparanase (HPSE-1) and metastatic melanoma.   
We provide, for the first time, evidence that 1) HPSE-1 is detected in in vivo cases of malignant 
melanoma, 2) a correlation exists between metastatic melanoma cancers and HPSE-1 expression, 
and 3) elevated HPSE-1 levels are found around microvessels in melanoma specimens.   
Heparanase has been shown to correlate with the metastatic potential of a variety of 
tumor-derived cell lines and tissue specimens, attributable to the enzyme involvement in ECM 
remodeling (Nakajima et al., 1986; Vlodavsky et al., 2001).   This list includes rat mammary 
adenocarcinoma, murine fibrosarcoma, human colon carcinoma and murine/human melanoma 
cell lines (Toyoshima et al., 1999; Vlodavsky et al., 2001; Zetser et al., 2003).  Low-metastatic 
murine T-lymphoma and melanoma cells transfected with the heparanase cDNA acquire a highly 
metastatic phenotype in vivo (Wang et al., 1997).  Thirdly, HPSE-1 is known to stimulate 
vascular endothelial cell invasion and to induce angiogenesis in several types of cancer 
(Vlodavsky et al., 2001).    
 Our results showed that HPSE-1 expression and localization in metastatic melanoma 
cases is significantly higher than in corresponding tissues surrounding melanoma metastases or 
in non-invasive, non-metastatic primary melanoma specimens. We also demonstrated its these 
findings indicate that heparanase may have a central role in promoting both cell expression and 
localization around blood vessels in melanoma clinical specimens.   Overall, invasion and 
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Figure 3.7  Elevated HPSE-1 Expression Around Blood Vessels in Metastatic Melanoma. 
(A) Nuclei stained by hematoxylin as a negative control.  (B) Hematoxylin staining with anti-
HPSE-1 PAb showing increased HPSE-1 expression in regions around blood vessels in 4 of 8 
brain metastatic melanoma samples. (C) Identification of vessels by endothelial staining with 
antibody to CD34.   Digital images were produced on an Axioplan microscope with Advanced 
Spot imaging program (Diagnostic Instruments Inc., Sterling Heights, MI) with 20x objective 
using identical conditions for all photographs. 
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angiogenesis are needed for the sustained growth of malignant melanoma. 
Many important endogenous angiogenic factors such as basic fibroblast growth factor 
(bFGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and 
others have been reported in malignant melanoma at significantly higher levels at invasive stages 
of the disease during its progression to the metastatic phenotype (Bogenrieder et al., 2003).   For 
example, VEGF overexpression can enhance growth of melanoma in the brain (Oku et al., 1998), 
being necessary but not sufficient for brain-metastatic growth (Yano et al., 2000).  Moreover, 
bFGF levels in patients with metastatic melanoma are also significantly higher than those in 
patients with non-invasive primary melanoma (Birck et al., 1999).  Finally, these factors are 
overexpressed in multiple malignant melanoma cell lines and in the serum of malignant 
melanoma patients (Ugurel et al., 2001) with most melanoma cells expressing HSPG that can act 
to concentrate these growth factors on their cell surface (Reiland et al., 2004).   Accordingly, two 
considerations can be made.  First, cleavage of HS within ECM and particularly within the 
basement membrane may be required for the migration of metastasizing melanoma cells and for 
remodeling of the vasculature during angiogenesis.  Second, HPSE-1 can directly promote 
angiogenesis by releasing heparin-binding angiogenic growth factors such as bFGF and VEGF 
that are trapped within the ECM and/or present on the cell surface. This idea is supported by the 
finding that HPSE-1 increases the angiogenic response to tumors and that enhanced HPSE-1 
mRNA expression correlates with tumor vascularity (Vlodavsky et al., 1999).    
The mechanisms by which heparanase facilitates cancer progression likely involves more 
than just remodeling ECM or releasing growth factors.    There is evidence that the fragments of 
heparan sulfate released on HS degradation maintain bioactivity and may, in fact, be more active 
than the native HS chains from which they are derived.   In a landmark study, it was discovered 
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that HS fragment can either promote or inhibit the growth and metastasis of these melanoma 
tumors (Liu et al., 2002b).    Thus, encoded within intact HS chains are cryptic structural 
elements that have the power to either positively or negatively impact the behavior of cancer 
cells.    HPSE-1 can be relevant because its enzymatic action produces these cryptic fragments 
with resulting biological consequences.   It will therefore be critical to determine the specific 
function of HS fragments generated by HPSE-1 degradation in melanoma cells,   and how these 
fragments modulate tumor cell behavior. 
As a further level of complexity, it is known that a balance between ECM degradative 
enzymes and their natural inhibitors controls the overall activity of these enzymes in invasion 
and metastasis.  For example, demonstration that ratios of ECM-degrading matrix 
metalloproteinases (MMPs) to tissue inhibitors of MMPs are important in cancer invasion and 
metastasis have been reported (DeClerck et al., 1992).  It is likely that HPSE-1 is also regulated 
by endogenous inhibitors in normal and tumor tissues.  Recently, eosinophil major basic protein 
has been reported as the first identified natural heparanase-inhibiting protein (Temkin et al., 
2004).  Possibly other natural HPSE-1 inhibitors can be present in melanoma cells (Keren et al., 
1989). 
In conclusion, our results indicate that HPSE-1 is expressed during metastasis and 
angiogenesis of melanoma cancers.   Thus, HPSE-1 can be a new target molecule to inhibit 
invasion, angiogenesis, and metastasis of this disease and a new prognostic factor of patients 
with malignant melanoma.  
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CHAPTER 4: DEVELOPMENT AND USE OF A BRAIN SLICE MODEL TO STUDY 
MECHANISMS OF CANCER METASTASIS TO THE BRAIN 
 
4.1 Introduction 
 Brain-metastatic melanoma and elevated levels of heparanase (HPSE-1) are known to be 
strongly correlated. Elevated levels of HPSE-1 have been shown to correlate with increased 
aggressiveness of metastatic tumors. It is known that patients with metastic disease show 
elevated levels of HPSE-1 in their sera and urine (Kelly et al., 2003; Nakajima et al., 1988), and 
post-operative patients with high HPSE-1 mRNA levels have a reduced chance of survival 
(Vlodavsky et al., 1999; Vlodavsky et al., 2001).  
 Malignant cells respond to paracrine and autocrine growth factor that are differentially 
expressed in several organs and tissues. These differential patterns of growth factor expression 
are a great determinant in the organ preference for metastatic colonization and growth. The 
primary and most well characterized paracrine factor is nerve growth factor (NGF) (Marchetti et 
al., 1990; Marchetti et al., 1993). NGF and NGF receptor expression are highly upregulated in 
melanoma progression to the highly aggressive brain metastatic-phenotype. NGF is also 
associated with enhancing heparanase production in brain metastatic melanoma (Marchetti et al., 
2004; Walch et al., 1999). 
The orthotopic brain slice model is a method where by cultures of nervous tissue can be 
maintained at the interface between the air and culture medium (Matsumura et al., 2000; Ohnishi 
et al., 1998; Stoppini et al., 1991). These cultures maintain brain cytoarchitecture such as cortical 
lamination and pyramidal cells. In addition, these tissues cultures retain the biochemical and 
electrophysiological properties of neural cells for up to one month in culture. This model makes 
it possible to investigate molecular events outside of the living body, which normally only occur 
in vivo (Matsumura et al., 2000; Ohnishi et al., 1998). The purpose our study was to use this 
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method to investigate the effects that both HPSE-1 and NGF have on brain metastatic melanoma 
cells and their invasive properties while being able to monitor the cells in in vivo-like conditions. 
Importantly, this brain slice model allows the ability to monitor tumor invasion at both 
quantitative and qualitative levels. In fact, brain-metastatic melanoma cells showed a 
significantly different invasion pattern depending on whether they where pre-treated with HPSE-
1 or with NGF.  Additionally, melanoma cells plated on these organotypic cultures showed a 
differential HPSE-1 expression at the protein level during time course experiments. 
 4.2 Materials and Methods 
4.2.1 Cell Lines and Their Transfections and Cell Culture Conditions 
The murine brain-metastatic cell line B16B15b was grown as a monolayer culture  
(Marchetti, 1993, Marchetti, 1996). Early-passage cells were stably transfected with enhanced 
green flurescent protein (EGPF) DNA using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA). 
B16B15b cells were transfected in a T25 flask, and for each tranfection 5µg of EGFP DNA and 
12 µl of LipofectAMINE 2000 were incubated for 5 minutes. Following incubation, 250 µl of 
Opti-MEM (Invitrogen) was added and incubated for an additional 20 minutes. The EGFP, 
LipofectAMINE 2000, Opti-MEM solution was added to cells in addition to fresh Ham’s F-12 
medium supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) (v/v) and 
blasticidin (10µg/ml) (Invitrogen) (1 ml). The flask was then placed in the incubator and the 
medium was changed within 6-24 hours. B16B15b-GFP cells were maintained as monolayer 
cultures in a 1:1 (v/v) mixture of Ham’s F-12 medium supplemented with 10% fetal bovine 
serum (FBS) (Hyclone) (v/v) and blasticidin (10 µg/ml).  Cells were maintained at 37°C in a 
humidified 5% CO2/95% air (v/v) atmosphere and passaged using EDTA (2 mM in PBS) before 
reaching confluence. 
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4.2.2 Brain Slice Model Detecting Malignant Melanoma Cell Invasion 
The brain tissue used for the organotypic brain slice models were obtained from 6-8 week 
old female C57BL/6 mice that were attained from Harlan Sprague Dawley (Indianapolis, IN). 
Prior to euthanasia they were quarantined for 1 week, and then housed in a barrier facility and 
fed Purine Lab Chow 5001. Mice were first anaesthetized with isoflurane and killed by 
decapitation. The mouse head was then plunged into 1% povidone-iodine solution. The brain 
was subsequently extracted from the skull and immediately submerged in ice cold sterile PBS.  
Next, the anterior portion of the brain was mounted and imbedded in a 3% agarose column with 
the anterior portion of the brain facing upward.  Finally, coronal sections of the brain that were 
500 µm thick were obtained with a vibratome. The brain sections were then transferred onto the 
polycarbonate membrane with a (0.4 µm) pore size in the upper chamber of a transwell tissue 
insert in a six well plate (Corning, Corning, New York), and 2 ml of DMEM/F12 medium 
supplemented with 10% FBS, and 100 units/ml of penicillin and streptomycin were added to the 
bottom well of the six well plate.  After allowing the brain to equilibrate for 24 hours, B16B15b-
GFP cell suspension (1x105 cells) was plated on the surface of the caudate nucleus and incubated 
for different amounts of time.   
4.2.3 Brain Slice Neuronal Viability Assays 
Neuronal viability in brain slices was assessed in terms of cellular uptake of propidium 
iodide (PI) (Sigma, St. Louis, MO) before and after the treatment with N-methyl-D-aspartic acid 
(NMDA) (Sigma). Morphological examinations were performed periodically on sections that had 
been incubated for longer than 72 hours. Brain slices were incubated with PI, after a 15 min 
exposure to 100 µM NMDA, for 1 hour or 24 hours. PI signals were viewed with a TRITC filter 
under a fluorescence microscope. PI was dissolved in a serum-free solution containing 75% 
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MEM, 25% phosphate buffered saline (PBS), 2 mM L-glutamine and 6.5 mg/ml glucose to a final 
concentration of 4.6 µg/ml as previously reported (Matsumura et al., 2000; Ohnishi et al., 1998). 
4.2.4 Brain Slice Model Invasion Assay with Heparanase and NGF-treated Cells 
 Invasive properties of melanoma cells were assayed by using an orthotopic brain slice 
model. For invasion assays, B16B15b-GFP cells were suspended in DMEM/F12 medium 
supplemented with 10%FBS, and 100 units/ml of penicillin and streptomycin at a concentration 
of 2x105 cells/µl. Directly before implanting melanoma cells on the brain slices either NGF or 
HPSE-1 was added to the cell suspension at a final concentration of 862 µM. Next, cells (1x105 
in 0.5 µl ) were implanted superficially on the caudate putamen of each brain slice, three brain 
slice treatment groups per six well plate, and incubated for 72 hours. As a negative control, B16 
B15b-GFP cells were suspended in the same medium previously mentioned and implanted on the 
brain slice without any treatment.   
4.2.5 Brain Slice Model Time Course Assay 
HPSE-1 expression patterns of malignant melanomas were monitored at different points 
of invasion through a time course assay. B16B15b-GFP cells were suspended in medium and 
plated as previously mentioned. Melanoma cells were implanted without any additional 
treatment and cells were incubated for 2, 12, and 24 hours respectively.   
4.2.6 Tissue Preservation 
After B16B15b-GFP cells and the brain slice were allowed to incubate, tissue sections 
were rinsed in sterile PBS and then fixed in formalin for 24 hours. Following formalin fixation, 
the brain slices were rinsed in sterile PBS and then incubated for 24 hours in 30% sucrose in PBS 
(Parlato et al., 2002). The tissue was rinsed with PBS again and flash frozen in isopentone over 
dry ice. The frozen sections were embedded in (Optimal Cutting Temperature medium) OCT and 
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mounted on a cryomold, and 10 µm thick serial sections were taken from a superior view of the 
500 µm brain slices cut at -28°C (Emmert-Buck et al., 1996; Sugiyama et al., 2002). 
4.2.7 Immunohistochemistry 
Immunohistochemical staining was performed using a Vectastain ABC kit (Vector 
Laboratories, Inc., Burlingame, CA) according to the instructions provided by the manufacturer. 
Briefly, formalin-fixed, OCT embedded tissue sections were mounted on poly-D-lysine coated 
silanized slides. Endogenous peroxidase was blocked by incubating the sections in 3.0% H2O2.  
After the blocking of nonspecific reactivity with rabbit serum for 30 min at room temperature 
(25°C), sections were incubated at 4°C for 60 min with the anti-rabbit polyclonal GFP anti-body 
raised against all variants of recombinant Aequorea GFP (Novus Biological Inc., Littleton, CO), 
or with anti-human HPSE-1 rabbit polyclonal anti-body raised against human heparanase 
(Pharmacia-Upjohn Inc., Kalamazoo, MI).  Following rinsing, slides were incubated with 
biotinylated anti-rabbit IgG and then with Vectastain ABC reagent.  Peroxidase activity was 
determined using NovaRED substrate kit (Vector), and the slides were counterstained with 
Mayer’s hematoxylin.  As a negative control, sections were subjected to normal serum blocking 
with omission of the primary antibody. 
4.2.8 Brain Slice Model Invasion Assays 
Serial sections were taken from brain slices that had been implanted with treated 
melanoma cells or corresponding non-treated control cells. Immunohistochemistry was 
performed on these serial sections with anti-GFP PAb in order to definitively mark the 
B16B15b-GFP cells that had invaded into the brain slice tissue.  Analysis of serial sections was 
performed blindly with a representative tissue sample. Invasion was measured in two different 
ways. First, invasion of melanoma cells was defined as the number of cells invading beyond the 
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surface of the brain per unit of area. The second method used to determine invasion was defined 
by measuring the depth of the most invasive cells per brain slice. The same counting area was 
used for each sample measurement followed by statistical analysis. 
 4.2.9 Statistical Analyses  
 All statistical analyses were conducted with the SAS® statistical package (version 9.1.2). 
To determine if there was a correlation between the number of cells invading and the depth of 
cell invasion, the Pearson correlation coefficient was calculated and significance was tested. In 
order to establish if this correlation could be used as a predictive model for overall cell 
invasiveness, regression analysis by treatment group was performed. Analysis of covariance was 
performed looking at heterogeneity of the slopes with cells as a covariate in order to conclude if 
there was a difference in invasion between treatment groups. All tests were considered 
significant at P < 0.05. 
4.3 Results 
 4.3.1 HPSE-1 Increases the Number of Invading Cells Using a Brain Slice Model 
 In order to determine the effect of HPSE-1 on brain tumor invasion, B16B15b-GFP cells 
were treated with HPSE-1 and implanted onto an orthotopic brain slice and incubated for 72 
hours.  Immunohistochemistry was performed looking to visualize GFP with anti-GFP 
polyclonal antibody on OCT-embedded brain slice sections.  Because the B16B15b-GFP 
melanoma cells were stably transfected, staining for GFP was a decisive way to mark invading 
cells with the results shown in Figure 4.1.  Upon analysis of serial brain sections, HPSE-1 
showed a two fold increase in the number of cells counted when compared to corresponding 
control groups (Figure 4.2).  However, when analyzing HPSE-1 invasion as a function of cell 
depth into the brain tissue there was a relatively small difference between HPSE-1 treated cells  
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Figure 4.1 The Brain Slice Model Invasion Assay 
Representative picture of invasion of tumor cells by using a brain slice model. Murine malignant 
melanoma cells stably transfected with green fluorescent protein B16B15b-GFP cells were 
plated on the caudate putamen of an organotypic brain slice as part of an invasion assay.  After 
incubating (72 hours) the cells on the brain slices were formalin fixed, frozen, sectioned further, 
and IHC stained for anti-GFP as a melanoma cell marker. (A) Cells plated with no treatment, (B) 
cells plated after treatment with heparanase (50 ng/ml).  
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Figure 4.2 Heparanase Invasion Assay Using a Brain Slice Model 
Extent of invasion into brain slices by murine brain metastatic melanoma cells as shown using 
quantitative analysis at 72 hours post implantation. The migration by GFP-expressing cells was 
measured by the number of cells invading beyond the surface of the brain per unit of area. 
Melanoma cells pre-treated with heparanase (50 ng/ml) had a greater number of cells invade into 
the brain slice per unit area than did control cells without pre-treatment. Heparanase treated cells 
sample (n = 75), Control group sample size (n = 100). Data were considered significant if 
p < 0.05.  
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and control cells (Figure 4.3).  Statistical analysis of both the HPSE-1 treated and corresponding 
control groups showed a good correlation between the number of cells invaded and the depth of 
cell invasion.  This correlation was further analyzed and determined to be a good predictive 
model for overall cell invasion.  Analysis of covariance was performed and showed a significant 
difference of HPSE-1 invasiveness when compared to corresponding control groups (Table 1). 
4.3.2 NFG Shows an Increase in Depth of Invasion 
After treating the cell with NGF (50 ng/ml) and following their incubation (72 hours), 
immunohistochemistry was performed to mark the invading tumor cells in order to correctly 
distinguish the cancer cell from normal brain tissue. Upon analysis of the NGF invasion assay, 
NGF influenced invasion in a completely different way.  NGF-treated samples, when analyzed 
for cell count, had fewer cells invade than untreated control groups (Figure 4.4). Conversely, 
when analyzing the depth of tumor cell invasion into the brain tissue NGF had higher depth than 
control groups (Figure 4.5). Statistical analysis showed a very good correlation between the 
number of cells invaded and depth of cell invasion for the control groups; however, the NGF 
treated groups had a poor correlation between cell number and depth of invasion. As a result, the 
NGF treated group made a poor model for cell invasiveness based on the assumption that cell 
number and depth correlate while the control group made for a strong predictive model. 
Conversely, when analysis of covariance was performed, NGF treated samples and control 
groups did not show a difference in invasiveness. NGF treatment groups showed a poor 
correlation because they had fewer cells invade, but the cells that did invade invaded further, 
which does not agree with the defined model. 
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Figure 4.3 Invasion Depth in the Presence of Heparanase Using a Brain Slice Model 
Depicting the depth of invasion into brain slices by murine brain metastatic melanoma cells as 
shown using quantitative analysis at 72 hours post implantation. The extent of migration by 
GFP-expressing cells was expressed by measuring the depth of the most invasive cells per brain 
slice. Melanoma cells pre-treated with of heparanase (50 ng/ml) showed no difference from cell 
without pre-treatment with regards to depth of invasion. Heparanase treated cells sample (n = 
75), Control group sample size (n = 100). Data were considered significant if p < 0.05.  
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Table 4.1 Statistical Analysis to Determine the Validity of Invasion Quantitation Methods 
 
 
Cell 
Treatment 
Pearson 
Correlation1 
Regression 
Analysis2 ANCOVA
3 Tukey Grouping4 
Control 0.59430 0.3532 0.99901 A 
Heparanase 0.59155 0.3499 0.86504 B 
1Pearson Correlation was to determine the correlation between the number of cells 
invading and the depth of cell invasion.   
2Regression analysis was performed, showing R-square values, to determine the predictive 
model for invasion.  
3Analysis of covariance was performed looking at heterogeneity of slopes.  
4Tukey’s grouping, designated by A and B, shows a significant difference between the 
treatment groups. p < 0.05 
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Figure 4.4 Nerve Growth Factor Invasion Assay Using a Brain Slice Model  
The extent of invasion in brain slices by murine brain metastatic melanoma cells as shown using 
quantitative analysis at 72 hours post implantation. The extent of migration by GFP-expressing 
cell was measured by the number of cells invading beyond the surface of the brain per unit of 
area. Melanoma cells pre-treated with NGF (50 ng/ml) showed no difference in the number of 
cells invading than control cells without NGF pre-treatment. NGF treated cells sample (n = 90), 
Control group sample size (n = 68). Data were considered significant if p < 0.05.  
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Figure 4.5 The Depth of Invasion with Invasion Assays in the presence of NGF 
Invasion into brain slices by murine brain metastatic melanoma cells as shown using quantitative 
analysis at 72 hours post implantation. The extent of migration by GFP-expressing cells was 
expressed by measuring the depth of the most invasive cells per brain slice. Melanoma cells pre-
treated with nerve growth (50 ng/ml) factor showed an increase in invasion when compared to 
cells without pre-treatment with regards to depth of invasion. NGF treated cells sample (n = 98), 
Control group sample size (n = 68). Data were considered significant if p < 0.05.  
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However, these results are correlative to previous findings who have investigated metastasis. 
NGF promotes tumor cell survival and aggressiveness in addition to its capabilities as a 
differentiation factor (Marchetti et al., 1993; Marchetti et al., 1996; Marchetti et al., 2001; 
Marchetti et al., 2004). 
4.3.3 Melanoma Cells Show a Correlation Between HPSE-1 Expression and 
Incubation Time 
 
 Immunohistoshemistry was performed on brain slice model OCT-embedded sections 
which had B16B15b-GFP cells implanted on them and incubated for 2, 12, and 24 hours. Upon 
staining for HPSE-1 with an anti-HPSE-1 polyclonal antibody, we observed a low level amount 
of HPSE-1 staining on the B16B15b-GFP cells that had been implanted on the brain slice for 
only 2 hours. Additionally, the cells that were incubated for 12 hours showed a definitive 
increase in HPSE-1 staining and an increase in invasion. Finally, the 24 hour time point showed 
the heaviest staining for HPSE-1 as well as the greatest amount of invasion (Figure 4.6).     
4.4 Discussion 
 Heparanase, which is an enzyme critically involved in degrading and remodeling ECM 
and basement membranes, has been shown to correlate with the metastatic potential of a variety 
of tumor-derived cell lines (Nakajima et al., 1983; Nakajima et al., 1984; Nakajima et al., 1988; 
Vlodavsky et al., 2001). Upon plating HPSE-1 treated brain-metastatic melanoma cells on brain 
slices, we were expecting a large number of cells to invade very aggressively. However, the 
HPSE-1 invasion assay had a high number of cells invade, but the cells didn’t invade deep into 
the tissue. In fact, there was little difference between the HPSE-1-treated cells and the control 
cells as to depth of invasion. This may be due to the fact that HPSE-1 degraded the basement 
membrane of the brain slice, but did not actually stimulate the cells to a  
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Figure 4.6 HPSE-1 Time Dependent Expression in Brain-Metastatic Melanoma Cells.  
B16B15b-GFP cells were implanted on the brain slices and at 2 hours. (A,D), 12 hours. (B,E), 
and 24 hours respectively. (C, F) post-implantation the experiments were stopped and IHC was 
performed. (A, E, F) Nuclei stained by hematoxylin with an isotyped matched mouse 
monoclonal antibody used as the primary antibody for a negative control for IHC staining.  (A, 
B, C) Hematoxylin staining with anti-HPSE-1 PAb showing increased HPSE-1 expression at 
increasing time points.  Digital images were produced on an Axioplan microscope with 
Advanced Spot imaging program (Diagnostic Instruments Inc., Sterling Heights, MI) with 20x 
objective using identical conditions for all photographs. 
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more aggressive metastatic state. The result from this would be the cells migrating into the area 
of the brain that the HPSE-1 degraded away, but the cells were not aggressive enough to actively 
invade farther into the tissue.     
The NGF receptor (p75NTR) is abundantly expressed in many melanoma tumors, and 
p75NTR is especially over-expressed during the later stages of melanoma progression (Marchetti, 
1993). It is known that malignant melanoma develops from cells undergoing an uncontrolled cell 
survival, growth, and proliferation to a neoplastic setting. This response is dependent upon these 
cells having an enhanced sensitivity to either autocrine or paracrine growth factors (Nicolson, 
1993). Through responsiveness to these growth factors, melanoma cells can become clonaly 
dominant within a tumor. This is what makes the paracrine factor NGF such an interesting 
molecule because it has the ability to influence cancer cells to progress into malignant 
aggressiveness and survivability. However, for NGF to be able to promote this effect, there has 
to be a high concentration of the p75NTR present on the cell surface. It is this p75NTR that makes 
the results of our invasion assay from the brain slice model of interest. NGF treated cells had a 
lower number of cells invading over time; however, cells that invaded migrated to a greater 
depth. This could mean that only a few of the cells overexpressed p75NTR. Consequently, when 
the NGF was added to our brain slice models only a few of the cells became clonally dominant, 
but the few that invaded did so aggressively (Marchetti et al., 1993; Marchetti et al., 2004; Walch 
et al., 1999). 
 The orthotopic brain slice model can present an in vitro model of the central nervous 
system in which neuronal architecture can be maintained. This model would create a co-culture 
between the melanoma cells and the brain tissue environment that allows a more realistic growth 
environment yet still being rather easy to manipulate treatment. First, it provides the ability to 
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analyze processes at the cell and molecular level while the cells are growing in a viable 
environment. Second, it allows the opportunity to run an invasion assay without having to add 
chemoattractants to the assay (Stoppini et al., 1991). Third, having the brain slice model for brain 
metastatic melanoma is especially helpful because it is thought that metastasis is dependent on 
certain host tissue properties, particularly the host microenvironment.  For these reasons, this 
model is of considerable use in the future research of brain metastatic melanoma. This model has 
been previously used in studying mechanisms of invasion in glioma cells and astrocytoma cells 
(Jung et al., 2001; Matzner et al., 1992; Ohnishi et al., 1998; Yoshida et al., 2002). This novel 
model has shown that brain derived neurotrophic factor mediates activity-dependent dendritic 
growth in neocortical interneurons in developing organotypic cultures (Jin et al., 2003). The 
othotopic brain slice model has proven useful in both the study of physiological and 
pathophysiological developmental processes.  
 
 50 
CHAPTER 5: SUMMARY AND CONCLUSIONS 
The first part of our studies was focused on in vivo experimentation and in looking at HPSE-1 
expression from tumors that metastasized to the lung. Since metastatic melanoma cells express 
high levels of HSPG, and their tumors grow highly vascularized, we analyzed melanoma tissue 
specimens for HPSE-1 expression from experimental animals as well as from patients. The 
results from these analyses demonstrated that HPSE-1 mRNA is significantly elevated in 
metastatic melanoma when compared to adjacent lung tissue. We showed that there were 
increased levels of HPSE-1 protein expression in metastatic melanoma clinical specimens while 
primary tumors result in low level HPSE-1 protein expression.  Another finding was that the 
presence of HPSE-1 appeared to be more concentrated around blood vessels and vascular regions 
in brain-metastatic melanoma specimens, a relevant finding since heparanase in known to be 
involved in angiogenesis. 
Since we had already shown that HPSE-1 expression is upregulated in tumor tissue when 
compared to normal corresponding tissue, we wanted to prove mechanistically that HPSE-1 
promotes invasion in in vivo-like conditions. Therefore, the objective of the second part of this 
project was to establish an organotypic culture system that can be of considerable usefulness in 
studying the process of brain-metastatic melanoma invasion. First, this model provides a better 
representation of the ECM molecules normally encountered by invading melanoma cells. 
Second, it gives the ability to monitor tumor invasion at both quantitative and qualitative levels. 
In fact, brain-metastatic melanoma cells showed a significant increase in invasion when treated 
with HPSE-1 versus untreated cells. Additionally, melanoma cells plated on these organotypic 
cultures showed differential expression of HPSE-1 at the protein level during a time-course 
experiment. 
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 Finally, this model is important because it can be used to determine mechanisms in 
cancer invasion and metastasis. First, it can be used to determine in vivo biological effects in 
conjunction with approaches that selectively block the expression of molecules implicated in 
cellular invasion. Furthermore, with this model, biological effects are quantifiable, hence it can 
be used to determine therapeutic efficiency.   
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